Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.

Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, Shin SS.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):167-79. doi: 10.1097/QAI.0b013e3181d9a330. Review. Erratum in: J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e37-8.

2.

Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy.

Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, Morroni C, Schoeman H, Knowlton AR, Maartens G.

AIDS. 2010 Jun 1;24(9):1273-80. doi: 10.1097/QAD.0b013e328339e20e.

3.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
4.

Virologic response using directly observed therapy in adolescents with HIV: an adherence tool.

Purdy JB, Freeman AF, Martin SC, Ryder C, Elliott-DeSorbo DK, Zeichner S, Hazra R.

J Assoc Nurses AIDS Care. 2008 Mar-Apr;19(2):158-65. doi: 10.1016/j.jana.2007.08.003. Review.

5.

Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.

Berg KM, Litwin A, Li X, Heo M, Arnsten JH.

Drug Alcohol Depend. 2011 Jan 15;113(2-3):192-9. doi: 10.1016/j.drugalcdep.2010.07.025. Epub 2010 Sep 15.

6.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
7.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
8.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
9.

A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.

Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A, Larsen R, Hader S, Anthony MN, Weidle PJ.

Clin Infect Dis. 2006 Jun 1;42(11):1619-27. Epub 2006 Apr 28.

PMID:
16652320
10.

Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.

Pence BW, Miller WC, Gaynes BN, Eron JJ Jr.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66.

PMID:
17146374
11.

A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.

Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR.

Arch Gen Psychiatry. 2010 Dec;67(12):1282-90. doi: 10.1001/archgenpsychiatry.2010.160.

12.

Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.

Arnsten JH, Litwin AH, Berg KM.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e33-4. doi: 10.1097/QAI.0b013e3181fcbcb4. No abstract available.

PMID:
21150506
13.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

14.

Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention.

Berg KM, Litwin AH, Li X, Heo M, Arnsten JH.

Clin Infect Dis. 2011 Nov;53(9):936-43. doi: 10.1093/cid/cir537. Epub 2011 Sep 2.

15.

Are there differences in disease progression and mortality among male and female HIV patients on antiretroviral therapy? A meta-analysis of observational cohorts.

Abioye AI, Soipe AI, Salako AA, Odesanya MO, Okuneye TA, Abioye AI, Ismail KA, Omotayo MO.

AIDS Care. 2015;27(12):1468-86. doi: 10.1080/09540121.2015.1114994.

PMID:
26695132
16.

The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.

McCabe CJ, Goldie SJ, Fisman DN.

PLoS One. 2010 Apr 13;5(4):e10154. doi: 10.1371/journal.pone.0010154.

17.

Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.

Dale S, Cohen M, Weber K, Cruise R, Kelso G, Brody L.

AIDS Patient Care STDS. 2014 Mar;28(3):136-43. doi: 10.1089/apc.2013.0329. Epub 2014 Feb 25.

18.

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.

Chang LW, Harris J, Humphreys E.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008494. doi: 10.1002/14651858.CD008494. Review.

PMID:
20393969
19.

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC; Pediatric AIDS Clinical Trial Group 381 Study Team.

J Infect Dis. 2004 Jul 15;190(2):271-9. Epub 2004 Jun 18.

PMID:
15216461
20.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002

Supplemental Content

Support Center